A combination of PD-1 and CTLA-4 inhibitors was used as a first-line treatment in this patient because the available evidence suggested that combination therapy may produce a higher tumor response rate than PD-1 inhibitors alone in metastatic NSCLC PD-L1 positive subgroups [2]. Here, PDCD1 is linked to non-small cell lung carcinoma.